Table 1.
Ongoing clinical trials testing the clinical profile of IDO1 inhibitors in cancer patients
| Agent | Indications | Phase | Status | Notes | Ref. |
|---|---|---|---|---|---|
| Indoximod | Brain neoplasms | I/II | Recruiting | Combined with temozolomide | NCT02052648 |
| Breast carcinoma | I/II | Active, not recruiting | Combined with an experimental DC-based vaccine | NCT01042535 | |
| II | Recruiting | Combined with docetaxel | NCT01792050 | ||
| Melanoma | I/II | Recruiting | Combined with ipilimumab | NCT02073123 | |
| Pancreatic carcinoma | I/II | Not yet recruiting | Combined with gemcitabine and paclitaxel | NCT02077881 | |
| Prostate carcinoma | II | Recruiting | Combined with sipuleucel-T | NCT01560923 | |
| INCB024360 | MDS | II | Active, not recruiting | As single agent | NCT01822691 |
| Melanoma | I/II | Recruiting | Combined with ipilimumab | NCT01604889 | |
| II | Recruiting | Combined with a multipeptide-based vaccine | NCT01961115 | ||
| Reproductive tract tumors | n.a. | Recruiting | As single agent | NCT02042430 | |
| I | Recruiting | Combined with the adoptive transfer of NK cells and IL-2 | NCT02118285 | ||
| I/II | Recruiting | Combined with DC-targeted NY-ESO-1 and polyICLC | NCT02166905 | ||
| II | Recruiting | As single agent | NCT01685255 | ||
| Solid tumors | I/II | Recruiting | Combined with a PDCD1-targeting monoclonal antibody | NCT02178722 | |
| NLG919 | Solid tumors | I | Recruiting | As single agent | NCT02048709 |
| IDO1-derived peptide | Melanoma | I | Recruiting | Combined with ipilimumab or vemurafenib | NCT02077114 |
Abbreviations: DC, dendritic cell; IDO1, indoleamine 2,3-dioxigenase1; IL-2, interleukin-2; MDS, myelodysplastic syndrome; n.a., not available; NK, natural killer; PDCD1, programmed cell death 1; polyICLC, polyinosinic:polycytidylic acid, stabilized in poly-L-lysine and carboxymethylcellulose. *Based on clinical trials not completed, withdrawn, terminated or suspended at the day of submission (source http://www.clinicaltrials.gov).